TY - JOUR
T1 - New antiretroviral drugs
T2 - A review of the efficacy, safety, pharmacokinetics, and resistance profile of tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir
AU - Hughes, Christine A.
AU - Robinson, Linda
AU - Tseng, Alice
AU - MacArthur, Rodger D.
N1 - Funding Information:
CA Hughes has received consultancy fees from Pfizer Canada and Abbott Laboratories. She has received speaker honoraria from Pfizer Canada, Abbott Laboratories and Merck Frosst. RD MacArthur has received research/grant support from Pfizer and Gilead. He is a consultant for GlaxoSmithKline, Gilead, Merck Frosst, Abbott Laboratories, Virco, Roche and Pfizer. He has received speaker honoraria from GlaxoSmithKline, Gilead, Roche, Virco, Merck Frosst, Tibotec, Abbott Laboratories and Pfizer. L Robinson has nothing to disclose. A Tseng has received grants from Abbott Laboratories, GlaxoSmithKline, Merck Frosst, Pfizer Canada and Tibotec. She has received speaker honoraria from Abbott Laboratories and Merck Frosst.
Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/10
Y1 - 2009/10
N2 - Background: The introduction and approval of new antiretroviral agents in the US and Canada bring new opportunities and new challenges. Arguably, for the first time ever, clinicians have the drugs necessary to achieve the goal of suppressing HIV RNA to levels less than 50 copies/mL in even the most treatment-experienced patients and in those with extensive drug-limiting resistance mutations. However, the use of these new agents is complicated by many drug-drug interactions and - to some extent - pre-existing mutations. To derive maximum durability from the use of these newer drugs, a thorough understanding of their indications and limitations is critical. Objective: To thoroughly review the six most recently approved or soon-to-be-approved antiretroviral drugs in the US and Canada: tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Methods: Discussion of the indications for, and pharmacokinetics, resistance profile, activity, toxicity, and clinical trials results of, the six new agents. Results/conclusions: These six new agents have resulted in marked progress towards the goal of being able to provide HIV-infected individuals with the drugs necessary to achieve decades of durable suppression of HIV without substantial toxicity.
AB - Background: The introduction and approval of new antiretroviral agents in the US and Canada bring new opportunities and new challenges. Arguably, for the first time ever, clinicians have the drugs necessary to achieve the goal of suppressing HIV RNA to levels less than 50 copies/mL in even the most treatment-experienced patients and in those with extensive drug-limiting resistance mutations. However, the use of these new agents is complicated by many drug-drug interactions and - to some extent - pre-existing mutations. To derive maximum durability from the use of these newer drugs, a thorough understanding of their indications and limitations is critical. Objective: To thoroughly review the six most recently approved or soon-to-be-approved antiretroviral drugs in the US and Canada: tipranavir, darunavir, etravirine, rilpivirine, maraviroc, and raltegravir. Methods: Discussion of the indications for, and pharmacokinetics, resistance profile, activity, toxicity, and clinical trials results of, the six new agents. Results/conclusions: These six new agents have resulted in marked progress towards the goal of being able to provide HIV-infected individuals with the drugs necessary to achieve decades of durable suppression of HIV without substantial toxicity.
KW - Antiretroviral therapy
KW - Darunavir
KW - Etravirine
KW - HIV
KW - Maraviroc
KW - Raltegravir
KW - Rilpivirine
KW - Tipranavir
UR - http://www.scopus.com/inward/record.url?scp=70349482329&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349482329&partnerID=8YFLogxK
U2 - 10.1517/14656560903176446
DO - 10.1517/14656560903176446
M3 - Review article
C2 - 19678794
AN - SCOPUS:70349482329
SN - 1465-6566
VL - 10
SP - 2445
EP - 2466
JO - Expert Opinion on Pharmacotherapy
JF - Expert Opinion on Pharmacotherapy
IS - 15
ER -